Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. US20170042948 - Modulation of fat storage in a subject by altering population levels of christensenellaceae in the GI tract

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

Claims

1. A method of inhibiting weight gain, promoting weight loss, or reducing adiposity in a mammalian subject in need, comprising oral administration of an effective amount of a composition comprising substantially purified Christensenella minuta bacteria wherein at least 50% of the Christensenella minuta in said composition are viable.
2. The method of claim 1, wherein the Christensenella minuta bacteria are lyophilized.
3. The method of claim 1, wherein 10 6 to 10 12 colony forming units (CFUs) of the Christensenella minuta bacteria are present in the composition.
4. The method of claim 3, wherein 10 8 to 10 11 colony forming units (CFUs) of the Christensenella minuta bacteria are present in the composition.
5. The method of claim 1, wherein said administration increases the levels of the Christensenella minuta bacteria relative to the levels of other bacteria in the gastrointestinal tract of said subject.
6. The method of claim 1, wherein said administration comprises administration on a daily or weekly basis.
7. The method of claim 1, wherein said subject is overweight, has obesity, has metabolic syndrome, and/or has diabetes.
8. The method of claim 1, wherein the composition is formulated as a food or drink.
9. The method of claim 1, wherein said subject is human.
10. A method of inhibiting weight gain, promoting weight loss, or reducing adiposity in a mammalian subject in need, comprising oral administration of a composition comprising 10 6 to 10 12 colony forming units (CFUs) of substantially purified Christensenella minuta bacteria wherein at least 50% of the Christensenella minuta in said composition are viable and wherein said composition is administered in a single dose or is split into multiple doses.
11. The method of claim 10, wherein the Christensenella minuta bacteria are lyophilized.
12. The method of claim 10, wherein 10 8 to 10 11 colony forming units (CFUs) of the Christensenella minuta bacteria are present in the composition.
13. The method of claim 10, wherein said administration increases the levels of the Christensenella minuta bacteria relative to the levels of other bacteria in the gastrointestinal tract of said subject.
14. The method of claim 10, wherein said administration comprises administration on a daily or weekly basis.
15. The method of claim 10, wherein said subject is overweight, has obesity, has metabolic syndrome, and/or has diabetes.
16. The method of claim 10, wherein the composition is formulated as a food or drink.
17. The method of claim 10, wherein said subject is human.